Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Antisense therapeutics

Akhtar, S., Hughes, M.D., Khan, A., Bibby, M., Hussain, M., Nawaz, Q., Double, J., and Sayyed, P. 2000. The delivery of antisense therapeutics. Advanced Drug Delivery Reviews 44(1), 3-21. [Pg.462]

Agrawal, S. and Kandimalla, E.R. (2000) Antisense therapeutics Is it simple as comple-mentary base recognition Mol. [Pg.45]

Zamecnik, P.C. (1996) History of antisense oligonucleotides. In S.Agrawal (ed.) Antisense Therapeutics, Humana Press, Totowa, pp. 1-12. [Pg.48]

The PK/PD properties of ASOs provide a framework for rapid drug development. Challenges to the promise of antisense therapeutics are not unlike those for any other new chemical entity, and they include proper application of the pharmacokinetic properties in order to select both target and delivery methods. The profound difference from the situation of small molecule discovery is the relative predictability of the pharmacokinetics, independent of target selection. [Pg.115]

Crooke, S. T. (1998). An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 8(2) 115-22. [Pg.234]

Flaherty KT, Stevenson JP, O Dwyer PJ (2001) Antisense therapeutics lessons from early clinical trials. Curr Opin Oncol 13 499-505... [Pg.84]

Prakash TP, Bhat B (2007) 2 -Modified oligonucleotides for antisense therapeutics. Curr Top Med Chem 7 641-649... [Pg.87]

Monteith DK, Levin AA. Synthetic oligonucleotides The development of antisense therapeutics. Toxicol Pathol 1999 27(1) 8-13. [Pg.574]

Antisense therapeutics, which had lost favor due to a well-publicized Phase-I human death in mid-2000, are already rebounding. Some forms of antisense show very high potential as antimicrobials. [Pg.929]

F. Bennett, Antisense Therapeutics Principles, Strategies and Applications, Marcel Dekker, New York, 2001, pp. 291-318. [Pg.162]

Pirollo, K.E, Rait, A., Sleer, L.S., and Chang, E.H. (2003) Antisense therapeutics from theory to clinical practice. Pharmacology and Therapeutics, 99, 55 77. [Pg.373]

P Nielsen. Antisense Therapeutics. Vol 4. Leiden SECOM Science Publishers, 1996, pp 76-84. [Pg.576]

Kole R, Vacek M, Williams T (2004). Modification of alternative splicing by antisense therapeutics. Oligonucleotides. 14 65-74. [Pg.1077]

Jason T L, Koropatnick J, Berg R W (2004). Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201 66-83. [Pg.1081]

Sandrasagra A, Leonard S A, et al. (2002). Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12 177-181. [Pg.1083]

Ball H A, Van Scott M R, Robinson C B (2004). Sense and antisense therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin. Rev. Allergy Immunol. 27 207-217. [Pg.1083]

Fig. 8.4. First-generation generalized structures of natural DNA (phosphodiester) and three antisense oligonucleotide derivatives tested as antisense drugs. (Adapted from Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997 76 151-160 with permission.)... Fig. 8.4. First-generation generalized structures of natural DNA (phosphodiester) and three antisense oligonucleotide derivatives tested as antisense drugs. (Adapted from Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997 76 151-160 with permission.)...
See other pages where Antisense therapeutics is mentioned: [Pg.194]    [Pg.216]    [Pg.462]    [Pg.585]    [Pg.313]    [Pg.496]    [Pg.491]    [Pg.303]    [Pg.108]    [Pg.108]    [Pg.109]    [Pg.113]    [Pg.246]    [Pg.16]    [Pg.512]    [Pg.536]    [Pg.712]    [Pg.208]    [Pg.196]    [Pg.86]    [Pg.87]    [Pg.806]    [Pg.264]    [Pg.344]    [Pg.193]    [Pg.1062]    [Pg.1069]    [Pg.1077]    [Pg.1096]    [Pg.329]    [Pg.329]    [Pg.329]   
See also in sourсe #XX -- [ Pg.244 , Pg.246 ]

See also in sourсe #XX -- [ Pg.568 ]

See also in sourсe #XX -- [ Pg.86 , Pg.87 ]



SEARCH



Antisense

© 2024 chempedia.info